Articles By Janet Pope, MD, MPH, FRCPC
“Age old” biomarkers in ILD and pulmonary fibrosis
At #ACR26, there was a poster on senescence being increased in SARD-ILD, including progressive pulmonary fibrosis, showing epithelial remodeling from DNA damage. This led me to look at the biomarkers of NISP (nonspecific interstitial pneumonia) that will transition to fibrosis, as the latter is considered irreversible and the former is potentially reversible.
Read Article
Is CAR-T cooling down in SARDs?
Tsao et al presented abstract #2773 consensus recommendations for CAR-T cell therapy in the SARDs from the Taiwan College of Rheumatology. They are thorough and outline a sensible approach.
Read Article
Do You Have to be Overweight for GLP-1s to Work?
Are there any data that GLP-1 RA drugs can be effective if a person has a normal BMI?
Read Article
Tips for safe use of allopurinol
These are tips and hopefully the patients are abstaining from moderate alcohol and are not tipsy! Here are 5 tips that may not be totally obvious.
Read Article
How many CAR-T’s do we need to test drive?
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Read Article
How to treat SLE in 2026 and beyond!
There are so many SLE trials, and over the last year, many new ideas have been suggested.
Read Article
‘Strong’ treatment predictions in inflammatory myositis
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Read Article
What should head-to-head studies in inflammatory arthritis teach us?
The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
Read Article
IgG4: Rare, but new treatments on the horizon
IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.
Read Article
Rheumatoid arthritis and the ‘big bang’ at the ACR!
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
Read Article
